Abeona Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Abeona Therapeutics, a leader in gene and cell therapy, announced participation in several virtual investor conferences. Key events include Citi’s 16th Annual BioPharma Virtual Conference (Sept. 8-10), H.C. Wainwright 23rd Annual Global Investment Conference (Sept. 13-15), SVB Leerink CybeRx Series (Sept. 22-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept. 30). Presentations will be available on their website, with webcasts accessible for 90 days post-event. Notable products in development include EB-101 for recessive dystrophic epidermolysis bullosa and AAV-based gene therapies for Sanfilippo syndrome.

NEW YORK and CLEVELAND, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that members of the company’s management will present and conduct one-on-one meetings at the following virtual investor conferences:

• Citi’s 16^th Annual BioPharma Virtual Conference on September 8-10, 2021 (one-on-one meetings only).
  
  
• H.C. Wainwright 23^rd Annual Global Investment Conference. The pre-recorded presentation will be available beginning September 13, 2021 at 7:00 a.m. ET throughout the conference ending September 15, 2021.
  
  
• SVB Leerink CybeRx Series Neuromuscular, Rare Diseases & Genetic Medicines on September 22-23, 2021 (one-on-one meetings only).
  
  
• Cantor Fitzgerald Virtual Global Healthcare Conference on Thursday, September 30, 2021 at 3:20 p.m. ET.
  

The company presentations will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com. The webcast replays will be available within 24 hours of the live presentation and will be accessible for 90 days.

About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its investigational autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel investigational AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s development portfolio also features AAV-based gene therapies for ophthalmic diseases with high unmet medical need. Abeona’s novel, next-generation AAV capsids are being evaluated to improve tropism profiles for a variety of devastating diseases. Abeona’s fully integrated gene and cell therapy cGMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and planned commercial production of AAV-based gene therapies. For more information, visit www.abeonatherapeutics.com.

Forward-Looking Statements
This press release contains certain statements that are forward-looking within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and that involve risks and uncertainties. We have attempted to identify forward-looking statements by such terminology as “may,” “will,” “believe,” “estimate,” “expect,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, numerous risks and uncertainties, including but not limited to the potential impacts of the COVID-19 pandemic on our business, operations, and financial condition, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the outcome of any future meetings with the U.S. Food and Drug Administration or other regulatory agencies, the impact of competition, the ability to secure licenses for any technology that may be necessary to commercialize our products, the ability to achieve or obtain necessary regulatory approvals, the impact of changes in the financial markets and global economic conditions, risks associated with data analysis and reporting, and other risks disclosed in the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q and other periodic reports filed with the Securities and Exchange Commission. The Company undertakes no obligation to revise the forward-looking statements or to update them to reflect events or circumstances occurring after the date of this press release, whether as a result of new information, future developments or otherwise, except as required by the federal securities laws.

FAQ

What is the schedule for Abeona Therapeutics' investor conferences in September 2021?

Abeona Therapeutics will participate in investor conferences on: Citi’s 16th Annual BioPharma Virtual Conference (Sept. 8-10), H.C. Wainwright 23rd Annual Global Investment Conference (Sept. 13-15), SVB Leerink CybeRx Series (Sept. 22-23), and Cantor Fitzgerald Virtual Global Healthcare Conference (Sept. 30).

Where can I find presentations from Abeona Therapeutics' investor conferences?

Presentations from the conferences will be available on Abeona Therapeutics' investor section of their website, with webcasts accessible for 90 days following the events.

What therapies is Abeona Therapeutics developing?

Abeona is developing gene therapies including EB-101 for recessive dystrophic epidermolysis bullosa and AAV-based therapies for Sanfilippo syndrome types A and B.

What is the focus of Abeona Therapeutics at the upcoming conferences?

Abeona Therapeutics will focus on its gene and cell therapy advancements, specifically in relation to their clinical programs and development portfolio.

What key products are highlighted by Abeona Therapeutics in their press release?

Key products include EB-101, an investigational therapy for recessive dystrophic epidermolysis bullosa, and ABO-102 and ABO-101, AAV-based gene therapies for Sanfilippo syndrome.